BTMD
biote Corp.
BTMD's outlook is improving, though it still trails on the overall score.
LLY
Eli Lilly and Company
LLY has the edge over BTMD overall, supported by stronger fundamentals and lower modeled downside.
BTMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Weak |
BTMD's revenue, profitability, cash flow and balance sheet are all currently under pressure.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
BTMD PE Valuation
BTMD has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
BTMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect BTMD's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over BTMD on the outlook, with more favorable revenue expectations.
BTMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.16 | — |
| Q3 2026 | -$0.11 | -114% |
| Q2 2026 | $0.10 | -89% |
| Q1 2026 | $0.43 | -31% |
| Q4 2025 | $0.74 | +289% |
| Q3 2025 | $0.80 | +31% |
| Q2 2025 | $0.91 | +75% |
| Q1 2025 | $0.62 | +35% |
| Q4 2024 | $0.19 | +46% |
BTMD has swung to a loss: it lost $0.11 per share over the past year, after a profit the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over BTMD on earnings quality, reporting a profit while its opponent remains loss making.
BTMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $43.3M | -9.6% |
| Q2 2026 | $44.2M | -9.5% |
| Q1 2026 | $44.9M | -8.3% |
| Q4 2025 | $46.4M | -6.9% |
| Q3 2025 | $48M | -6.7% |
| Q2 2025 | $48.9M | -0.6% |
| Q1 2025 | $49M | +4.7% |
| Q4 2024 | $49.8M | +9% |
BTMD's revenue has slid since its 2024 peak: $43M last quarter, down 9.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.7% | -12 points |
| Q2 2026 | -7.9% | -30 points |
| Q1 2026 | 7% | -13 points |
| Q4 2025 | 15% | +9.2 points |
| Q3 2025 | 17% | -6.5 points |
| Q2 2025 | 22% | +9.4 points |
| Q1 2025 | 20% | -2.5 points |
| Q4 2024 | 5.5% | -6.5 points |
BTMD's operating margin was 5.7% last quarter, down 11 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over BTMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over BTMD on profitability, with a higher operating margin.
BTMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -92% |
| Q2 2026 | -$3.7M | -171% |
| Q1 2026 | $3.5M | -27% |
| Q4 2025 | $6.5M | -39% |
| Q3 2025 | $13.6M | -3.1% |
| Q2 2025 | $5.3M | -29% |
| Q1 2025 | $4.8M | -27% |
| Q4 2024 | $10.7M | +50% |
BTMD still generates free cash flow, though less than at its 2024 peak: $7M over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over BTMD on cash flow, with more consistent year-over-year improvement.
BTMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.2% | -1.2M shares |
| 1 year | -25% | -9.3M shares |
| 3 years | -12% | -3.6M shares |
BTMD has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.4M |
| Q2 2026 | $4.8M |
| Q1 2026 | $1.1M |
| Q4 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $1.5M |
| Q1 2024 | $4.1M |
BTMD spent $7M buying back its own shares over the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
BTMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 8.6x | High |
| Q2 2026 | 5.9x | High |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 2.0x | Healthy |
| Q3 2025 | 2.1x | Moderate |
| Q2 2025 | 2.2x | Moderate |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.9x | Healthy |
BTMD's net debt is about 8.6 years of its operating earnings (EBITDA), up from 2.1 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over BTMD on leverage, with a lower net debt burden relative to earnings.
BTMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.3 | Neutral |
| Stochastic | 6.0 | Oversold |
BTMD's weekly RSI is 32 (neutral) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
BTMD PE vs Healthcare Sector
| Metric | BTMD | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
| PE % | 73 | 36 | 37 pts above |
BTMD has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
BTMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.11 | 7.2% below |
| 20 week MA | $1.54 | 33% below |
| 50 week MA | $1.89 | 46% below |
| 100 week MA | $2.87 | 64% below |
| 200 week MA | $4.28 | 76% below |
BTMD is in a downtrend: it's below all five of its weekly moving averages, and 76% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over BTMD on trend strength, trading above more of its moving averages.
BTMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $10.1 | $9.85 | -2% |
| 2022 | $9.85 | $3.91 | -60% |
| 2023 | $3.91 | $4.94 | +26% |
| 2024 | $4.94 | $5.99 | +21% |
| 2025 | $5.99 | $2.68 | -55% |
| 2026 YTD | $2.68 | $1.03 | -62% |
BTMD has finished lower in three of the last five years. It's down 62% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over BTMD on returns for 2026, with the stronger performance.